Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
transaction | NORD | Warrant | Exercise of out-of-the-money derivative security | $34K | +3.4K | +0.64% | $10.00 | 533K | Aug 30, 2024 | Common stock | 600K | $10.00 | Direct | |
transaction | NORD | Warrant | Exercise of out-of-the-money derivative security | $32K | +3.2K | +0.61% | $10.00 | 529K | Oct 3, 2024 | Common stock | 600K | $10.00 | Direct | |
transaction | NORD | Warrant | Exercise of out-of-the-money derivative security | $120K | +12K | +2.37% | $10.00 | 517K | Oct 17, 2024 | Common stock | 600K | $10.00 | Direct | |
transaction | NORD | Warrant | Exercise of out-of-the-money derivative security | $35K | +3.5K | +0.69% | $10.00 | 514K | Nov 1, 2024 | Common stock | 600K | $10.00 | Direct | |
transaction | NORD | Warrant | Exercise of out-of-the-money derivative security | $35K | +3.5K | +0.69% | $10.00 | 510K | Nov 6, 2024 | Common stock | 600K | $10.00 | Direct |
Id | Content |
---|---|
F1 | Shares acquired in connection with the acquisition by Nordicus Partners Corporation through a share exchange with the shareholders of Bio-Convert ApS (893,268 shares) and in connection with the acquisition by Nordicus Partners Corporation of Orocidin A/S (183,144 shares) on November 12, 2024. |